Who we are

Pushing the Boundaries of Innovation to Improve Patient Outcomes

VERO Biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (iNO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions.

We stand among the youngest mature companies—innovative, fast-growing, and backed by a high-value portfolio. As a stable and trusted partner, VERO Biotech is deeply committed to patients and practitioners in the acute care setting.

Newborn in a hospital

Our mission

Our mission is to advance patient care with innovative solutions and unparalleled customer service.

We are committed to improving the lives of patients by developing innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever nitric oxide treatment is needed.

We strive to exceed customer expectation in terms of safety, efficiency, and value by focusing on the science, development, and commercialization of our innovations.

Milestones

VERO Biotech sets the standard for growth and stability, driven by a proven history of rapid innovation.

  • 2025

    Received FDA approval for use of 3rd Generation GENOSYL® DS with anesthesia in the surgical suite and inter-hospital transport.

  • 2024

    Awarded the American Association for Respiratory Care (AARC) Zenith Award

  • 2023
    • Received FDA approval for the 3rd Generation tankless inhaled nitric oxide delivery system (GENOSYL® DS) in the acute care setting.
    • Received FDA approval for use of 2nd Generation GENOSYL® DS with anesthesia in the surgical suite.
    • Raised $30 million in funding to accelerate commercialization.
    • Recognized as a technological breakthrough by Premier Inc.
  • 2022

    Awarded the Georgia Bio Golden Helix “Innovation Award” for breakthrough development of GENOSYL® Delivery System

  • 2021
    • Secured $50 million funding from Runway Growth Capital
    • Receives up to $100 million investment from MVM Partners to support the growth of GENOSYL® DS
  • 2020
    • Launched 2nd Generation GENOSYL® DS in the acute care setting
    • Granted expanded access emergency use for the treatment of patients with COVID-19
    • COVID patient treated at home with GENOSYL® DS
    • Received FDA approval for use of 2nd Generation GENOSYL® DS in MRI and Inter-Hospital Transport
  • 2019

    FDA approval 1st Generation GENOSYL® DS, tankless inhaled nitric oxide delivery system, in the acute care setting

Meeting

Careers

Where Passion Meets Purpose: Innovative Careers Await

Looking for an exciting next step?

Join our passionate, purpose-driven team dedicated to transforming patient care. We seek innovative, driven, high-integrity talent to help us discover, develop, and deliver our future products.

Apply Now